Signoriello et al. found that CSF adiponectin levels are higher in MS patients than in controls, with particularly high levels in primary progressive MS (PPMS) compared to relapsing–remitting MS (RRMS). This evidence concerns the gene ADIPOQ and myeloid sarcoma.